Gynecologic Oncology

A large-scale study of HPV testing and Pap smear for cervical cancer screening confirms that women can safely extend screening intervals from 1 to 3 years.

Dr. Markman on HPV Testing to Detect Cervical Cancer

Dr. Pecora on HPV Cervical Cancer Findings

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Markman Discusses the Importance of Cancer Screening

Fiona McCaughan on Nurses Facilitating Intraperitoneal Chemotherapy Completion

Investigators have reported an increased risk of invasive breast cancer in postmenopausal women who are or were cigarette smokers

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

More than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

Investigators in a cooperative group trial reported that modifications in a chemoradiation regimen for locally advanced vulvar cancer boosted both clinical and pathologic complete response rates

The results of a small clinical trial showed that low-level expression of a microRNA correlated with improved progression-free survival

Results of a phase II cooperative-group trial showed that the targeted agent cetuximab demonstrated minimal activity in patients with advanced, platinum-resistant cervical cancer

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)

Nektar Therapeutics announced that its oncology drug candidate, NKTR-102, has been granted orphan drug status

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Exposure to air pollution at certain times in a woman's life can leave her more susceptible to premenopausal breast cancer

Cervical cancer affects about 470,000 women each year and now the disease has a new tool to combat its spread

Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight

A breast cancer diagnosis is a highly distressing, life-changing experience

A team of researchers explored the use of drugs in terms of breast cancer prevention strategies

Iniparib remains an intriguing therapeutic possibility despite failing to meet its phase III primary endpoints

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

For the first time in at least 3 decades, the rate of women dying from lung cancer in the United States is declining